Clinical Trial Update: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating perioperative pembrolizumab for patients with resectable oligometastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligometastatic Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Oligometastatic Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN